The present invention relates to a restoration material used as a burn covering material and/or a regenerative scaffold for burns for use in the treatment of burns, and in particular serious burns.
The severity of a burn is determined by the area and depth. Depth is classified into first to third degrees based on the color tone of the surface. A second-degree burn is a burn that reaches the dermis, and a third-degree burn is a state where the skin is entirely damaged.
When the body suffers second-degree burns to 30% or more of the body surface area or third-degree burns to 10% or more of the body surface area, intensive care at an emergency center becomes necessary.
Third degree burns in the region subjected to emergency surgery will generally have thick necrotic tissue and will be subjected to surgical treatment, which prevents the application of a general-purpose wound dressing. If there is the risk of local infection occurring over time, eschar and necrotic tissue should be removed as soon as possible, and skin grafting should be performed after observing the formation of granulation tissue from the surrounding area. However, due to insufficient wound bed preparation (that is, favorable granulation), which is indispensable when grafting is performed, there is often the problem of deterioration in the patient's condition and even death due to poor regeneration (that is, difficulty in achieving engraftment of transplanted skin).
According to the “Clinical Practice Guidelines for Management of Burn Care” [Revised 2nd Edition], 2015″ published by the Japanese Society for Burn Injuries, most reports about wound dressings used on burns relate to second degree burns. There is no wound dressing that has been actively used on third degree burns. Wound dressings used for burns are roughly divided into foam materials, fiber materials, and colloidal materials, which are selectively used as appropriate according to shape and ability to absorb exudate.
Until now, no treatment method for third-degree burns has had an effect of preventing infection and promoting favorable granulation, and at present there is no choice but to rely on the vitality and immunity of the patient.
Although it is necessary to grow granulation tissue at an early stage, there is no effective material to achieve this. Forming favorable granulation at an early stage and performing a skin graft at an early stage without causing infection are effective in prolonging the life of a patient with serious burns.
Amniotic membrane is a tough biological membrane composed of collagen and elastic fibers, and raw amniotic membrane has been reported as a useful covering material for trauma and burns (see Non-Patent Document 1). However, raw amniotic membrane has not been available immediately when needed and has been complicated to store and handle, which has limited its use in actual clinical practice. On the other hand, dry amniotic membrane (or “hyper-dry huma amniotic membrane”: hereinafter, “HD-AM”) produced by a specific drying process has also been announced (see Patent Literature 1 and Non Patent Literature 2).
The present inventors created burn model animals with first to third degree burns, and histologically, immunochemically, and molecularly confirmed that HD-AM promotes granulation growth at dermal defects or subcutaneous tissue defects of the burn model animals. In other words, the present inventors completed the present invention by clarifying that HD-AM functions as a scaffold for cells, induces growth factors and cell migration chemokines, and regulates differentiation to M2 macrophages to promote local anti-inflammation and tissue regeneration, thereby contributing to tissue regeneration.
The present invention will be described in detail below.
A restoration material for burns according to the present invention is a restoration material to be used in treatment of burns as a covering material for burns and/or a regenerative scaffold for burns, the restoration material being a dry amniotic membrane produced by performing a drying process on raw amniotic membrane that surrounds a fetus of an animal, including a human, wherein the dry amniotic membrane has been dehydrated and dried so as to enable storage in an aseptic dry atmosphere, and amniotic membrane produced by rehydrating the dry amniotic membrane by immersion in water or a buffer retains epithelial cells, basement membrane, and connective tissue constituting the raw amniotic membrane.
By using this configuration, when the restoration material is used as a covering material and/or a scaffold for regeneration of a dermal defect or subcutaneous tissue, especially for a patient with a severe burn, secretion of physiologically active substances, such as inflammatory cytokines and growth factors, is promoted at the wound site of the severe burn. The inflammatory cytokines protect against infection by foreign substances from the outside, and wound healing of the severe burn is additionally promoted through active effects, such as promotion of secretion of VEGF and TGF-b.
The restoration material may be a covering material and/or a scaffold for a treatment process of severe burns that are second-degree burns and/or third-degree burns.
Use of a restoration material for burns according to the present invention is use of a restoration material for burns to be used in treatment of burns as a covering material for burns and/or a regenerative scaffold for burns, the restoration material being a dry amniotic membrane produced by performing a drying process on raw amniotic membrane that surrounds a fetus of an animal, including a human, wherein the dry amniotic membrane has been dehydrated and dried so as to enable storage in an aseptic dry atmosphere, and amniotic membrane produced by rehydrating the dry amniotic membrane by immersion in water or a buffer retains epithelial cells, basement membrane, and connective tissue constituting the raw amniotic membrane.
This use may be use as a covering material and/or a scaffold for a treatment process of severe burns that are second-degree burns and/or third-degree burns.
By applying the HD amniotic membrane, cell infiltration becomes active in an early stage post-injury, and by holding infiltrating cells as a scaffold, it becomes possible to promote the secretion of physiologically active substances, such as inflammatory cytokines and growth factors, at the wound site. It was established that inflammatory cytokines protect against infection by foreign substances from outside, which promotes the secretion of VEGF and TGF-b, and promotes neovascularization and favorable granulation formation. On the other hand, secretion of IL-10, a cytokine that suppresses inflammation, was stimulated, and CD163-positive M2 cells had significantly proliferated by POD7.
Immediately after the burn, a full thickness of skin of the same site was excised to create an open wound.
A dried amniotic membrane manufactured by a specified drying process (called “hyperdrying”) is, for example, the dried amniotic membrane described in Patent Literature 1. That is, raw amniotic membrane placed in a processing tank is continuously heated by a far-infrared heater provided inside the processing tank, and a depressurization operation, in which the inside of the processing tank is placed in a depressurized state, and irradiation of the raw amniotic membrane with microwaves from a microwave irradiating device provided inside the processing tank to apply energy to water molecules present inside the amniotic membrane and cause drying during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank toward atmospheric pressure were performed. In the dried amniotic membrane (HD-AM) manufactured by repeating the above process a plurality of times, the amniotic membrane cells themselves are inactivated but the cell and tissue structures are retained.
Third degree burns in the region of emergency surgery fundamentally have thick necrotic tissue and are indicated for surgical treatment, which prevents the application of a general-purpose wound dressing. If there is the risk of local infection occurring over time, eschar and necrotic tissue should be removed as soon as possible, and skin grafting should be performed after observing the formation of granulation tissue from the surrounding area. However, due to insufficient wound bed preparation (that is, favorable granulation), which is indispensable when grafting is performed, there is often the problem of deterioration in the patient's condition and even death due to poor regeneration (difficulty in achieving engraftment of the transplanted skin).
In the present embodiment, HD-AM is placed as a covering material and a scaffold. Placing HD-AM as a covering material and a scaffold on the wound part of a severe burn promotes protection against infection and neovascularization through a transient elevation of inflammatory cytokines and VEGF, which then changes to a decrease in the inflammatory cytokines and VEGF and an increase in anti-inflammatory cytokines, which promotes active effects such as high-quality granulation.
In the present embodiment, when HD-AM is used as a covering material and a scaffold, as one example, the HD-AM may be formed into an appropriate shape with scissors or the like in keeping with a wound site of a burn, severe burn, or the like where a general-purpose wound covering material cannot be used, and a drainage hole may be fabricated.
As depicted in
Note that the handling of laboratory animals was approved by the Institutional Animal Care and Use Committee of the University of Toyama in accordance with the guidelines of the National Institutes of Health. The experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee of the University of Toyama.
Human amniotic membrane is mainly composed of three layers, a monolayer epithelial layer (hereinafter “epithelium”), a thin basement membrane (hereinafter “basement membrane”), and an avascular stromal layer (hereinafter “stroma”) (see the HD-AM part of
Each of the groups (“HD-AM(−)” and “HD-AM”) contained five mice which were evaluated 1 day post operation (POD 1), 4 days post operation (POD 4), and 7 days post operation (POD 7), meaning a total of thirty animals were used. The wounds were covered with stainless steel mesh (0.06 mm 1, 150 m/s) to prevent deviation of the HD-AM and/or wound covering due to mouse behavior.
To perform histological observation, the wounded part produced by the burn was collected from each mouse on POD 1, POD 4, and POD 7 and embedded in paraffin. Sections sliced from the paraffin block were stained with hematoxylin-eosin (H&E) and Azan. In addition, immunohistochemical staining was also performed for CD163, Iba1, TGβ-1 (transforming growth factor beta-1), VEGF (vascular endothelial growth factor), CD31, and aSMA. Stained tissue was imaged using a Leica DMRBE microscope (Leica, Wetzlar, Germany) and a DP73 system (Olympus, Tokyo, Japan).
Azan staining makes it easy to distinguish between collagen fibers and fibrin for observation of granulation tissue. The thickness of granulation tissue containing collagen fibers was measured using the Olympus CellSens imaging program (version 1.7; Olympus, Tokyo, Japan). On the 4th day after treatment (POD 4), regardless of whether HD amniotic member was applied, the appearance of a layer of collagen membrane between the subcutaneous tissue and muscle layer of the surrounding normal tissue was confirmed. Since movement of infiltrating cells at the edge and granulation formation were observed for this membrane, regions were determined as depicted in
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
To extract mRNA from the granulation tissue from wounds caused by burns, target sites were selectively collected from each sample. When sampling was performed, the granulation tissue was dissected in the same mariner for all specimens, which were made as anatomically uniform as possible so as not to be affected by differences in sampling sites and regions. Total mRNA was extracted from tissue using Isogen II (Nippon Gene Co. LTD., Tokyo, Japan) according to the manufacturer's instructions. A 3 μg part of the mRNA was treated with deoxyribonuclease I (DNase I, Sigma-Aldrich, Inc., Tokyo, Japan) for 15 minutes at room temperature. cDNA was synthesized using 500 ng of DNase I-treated RNA using the ReverTra Ace qPCR RT Kit (made by Toyobo Co., Ltd., Osaka, Japan). Gene expression was subjected to real-time RT-PCR analysis using Brilliant SYBR Green QRT-PCR Mix (Stratagene; Agilent Technologies Japan Ltd. Japan) using an Mx3000P quantitative polymerase chain reaction (qPCR) system (Stratagene; Agilent Technologies Japan Ltd, Japan). On POD 1, POD 4, and POD 7, mRNA was extracted from each of five mice in each group, and the growth factors TGFβ130, VEGFA31, α-SMA32, bFGF33, and PDGF34, the cell migration chemokines CXCL-535 and SDF-135, CD163 which is a marker for anti-inflammatory M2 macrophages, the anti-inflammatory cytokine IL-1037, the inflammatory cytokine IL-637, tumor necrosis factor-alpha (TNF-α38), and inducible nitric oxide synthase (iNOS38) were measured in triplicate.
To establish that the variations in cytokines were postoperative changes, tissue was collected immediately after creating five model mice, and the mRNA expression level of each primer immediately after the operation was examined as POD 0. The expression level of each mRNA was corrected with GAPDH as an internal control, and relative comparisons were made based on the mean value of the HD-AM(−) group on POD 7. The sequence of the primers used here is depicted in
The thickness of the granulation tissue at the wound part was measured in each group (indicated by yellow arrows) and was compared on POD 1, POD 4, and POD 7 (see
Cell Infiltration into HD-AM
Cell infiltration into the HD-AM was observed for the HD-AM group (see
The inflammatory cytokine iNOS significantly increased in the HD-AM group on POD 4 and POD 7. The inflammatory cytokine IL-6 was transiently elevated on POD 4. The anti-inflammatory cytokine IL-10 was significantly elevated for the HD-AM group on POD 4 and POD 7. CD163, which indicates anti-inflammatory M2 macrophages, was significantly elevated in the HD-AM group on OD 7 (see
CD 163, a marker for anti-inflammatory M2 macrophages that act on tissue remodeling, indicated significantly higher values for the HD-AM group on POD7 (see
Regarding anti-inflammatory cytokines, IL-10 also tended to be higher when amniotic membrane was placed. These results indicate that the application of HD amniotic membrane has the effect of promoting healing of a wound.
Localization of CD31, which indicates neovascularization, TGFβ-1, which also contributes to growth suppression, cell differentiation, and apoptosis induction, VEGF, a vascular endothelial growth factor, and CD163, which indicates anti-inflammatory M2 macrophages, were investigated by immunohistochemical staining. On POD 7 for the HD-AM group, neovascularization was observed at the granulation site (tissue 3) in a state that extended in a direction toward tissue 1 (see
Using the drying device depicted in
The drying device in
The treatment tank 10 is also provided with a microwave irradiating device 30 which performs, when a pressure recovery operation has been performed from a reduced pressure state, drying while applying energy to water molecules in the amniotic membrane
Drying tank heating temperature: 50° C., FIR: 50° C., Stop valve: 37%, Maximum ultimate pressure 0.34 kPa Dry running maximum ultimate pressure 0.33 kPa
Drying method
Process Complete when Atmospheric Pressure is Restored
Dried amniotic membrane (HD-AM) is manufactured by a specific drying process, that is, raw amniotic membrane that has been placed inside a processing tank is continuously heated by a far infrared heater provided inside the processing tank while performing a depressurization operation that reduces the pressure inside the processing tank and irradiation of the raw amniotic membrane with microwaves from a microwave irradiating device provided inside the processing tank to apply energy to the water molecules present inside the amniotic membrane and dry the amniotic membrane during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank toward atmospheric pressure. By repeating the above multiple times, it is possible to improve storage stability and handling of the dried amniotic membrane while preserving the cell and tissue structure. This is a treatment method which, by using dried amniotic membrane when covering a dermal defect or subcutaneous tissue of a patient with a severe burn and/or during tissue regeneration (favorable formation of granulation that accompanies neovascularization), can quickly realize a skin graft, which is essential for treating third-degree burns and the like. In addition, by using amniotic membrane to prevent infection at a wound caused by a burn, it is possible to increase the patient's survival rate and achieve therapeutic effects (that is, eliminate the risk of keloids).
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/JP2020/044438 | 11/30/2020 | WO |